<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01425970</url>
  </required_header>
  <id_info>
    <org_study_id>AI472-003</org_study_id>
    <secondary_id>INH-189-003</secondary_id>
    <nct_id>NCT01425970</nct_id>
  </id_info>
  <brief_title>Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin</brief_title>
  <official_title>A Phase II, Randomized, Multi-center, Two Part Study of the Safety and Efficacy of Double-blind, Placebo-controlled INX-08189 in Adjunctive Treatment With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Study Part A, and Open-label INX-08189 in Adjunctive (Interferon Free) Treatment With Daclatasvir and/or Ribavirin (Copegus®) in Study Part B, in Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Part A: The purpose of this study is to evaluate the safety and tolerability of INX-08189 and
      placebo with Peginterferon alfa-2a and Ribavirin during 12 weeks of treatment

      Part B: The purpose of this study is to evaluate the safety and tolerability of INX-08189
      with Ribavirin or INX-08189 with Daclatasvir or INX-08189 with Daclatasvir and Ribavirin
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Data Monitoring Committee is appointed for Part A only

      Masking: Part A of this study is Double blind and the Part B is Open Label
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Termination of study was due to safety reasons
  </why_stopped>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Change in Hepatitis C Viral Load Measurements at protocol specific timepoints</measure>
    <time_frame>Weeks -6, 0, 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 28, 36, 48</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: proportion of subjects with SVR defined as HCV RNA ≤ LOQ (Limit of Quantitation)</measure>
    <time_frame>At treatment weeks 12</time_frame>
    <description>SVR = Sustained virologic response
HCV RNA = Hepatitis C virus ribonucleic acid</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: proportion of subjects with SVR defined as HCV RNA ≤ LOQ</measure>
    <time_frame>Post treatment week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessments is measured by Physical Exams, vital signs, laboratory assessments, ECGs, pregnancy test, viral resistance testing, adverse event assessment</measure>
    <time_frame>up to 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with RVR (Rapid Virologic Response), undetectable HCV RNA</measure>
    <time_frame>At treatment weeks 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with Complete EVR (Early Virologic Response), undetectable HCV RNA</measure>
    <time_frame>At treatment weeks 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with Extended RVR</measure>
    <time_frame>At treatment weeks 4 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with SVR24</measure>
    <time_frame>Post treatment week 24</time_frame>
    <description>SVR24 = sustained virologic response at 24 weeks after the cessation of treatment</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">210</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>25 mg INX-08189 + Pegylated interferon alfa-2a + Ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PART A Arm 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50 mg INX-08189 + Pegylated interferon alfa-2a + Ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PART A Arm 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mg INX-08189 + Pegylated interferon alfa-2a + Ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PART A Arm 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Pegylated interferon alfa-2a + Ribavirin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PART A Arm 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mg INX-08189 + Ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PART B Arm 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mg INX-08189 + Ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PART B Arm 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daclatasvir + INX-08189 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PART B Arm 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daclatasvir + INX-08189 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PART B Arm 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daclatasvir + INX-08189 50 mg + Ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PART B Arm 5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INX-08189</intervention_name>
    <description>Tablet, Oral, 25 mg, Once daily (QD), 12 weeks</description>
    <arm_group_label>25 mg INX-08189 + Pegylated interferon alfa-2a + Ribavirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INX-08189</intervention_name>
    <description>Tablet, Oral, 50 mg, Once daily (QD), 12 weeks</description>
    <arm_group_label>50 mg INX-08189 + Pegylated interferon alfa-2a + Ribavirin</arm_group_label>
    <arm_group_label>Daclatasvir + INX-08189 50 mg + Ribavirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INX-08189</intervention_name>
    <description>Tablet, Oral, 100 mg, Once daily (QD), 12 weeks</description>
    <arm_group_label>100 mg INX-08189 + Pegylated interferon alfa-2a + Ribavirin</arm_group_label>
    <arm_group_label>100 mg INX-08189 + Ribavirin</arm_group_label>
    <arm_group_label>Daclatasvir + INX-08189 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matching with INX-08189</intervention_name>
    <description>Tablet, Oral, 0 mg, Once daily (QD), 12 weeks</description>
    <arm_group_label>Placebo + Pegylated interferon alfa-2a + Ribavirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pegylated interferon alfa-2a</intervention_name>
    <description>Syringe, Subcutaneous injection, 180 μg, Once per week, 12 weeks</description>
    <arm_group_label>25 mg INX-08189 + Pegylated interferon alfa-2a + Ribavirin</arm_group_label>
    <arm_group_label>50 mg INX-08189 + Pegylated interferon alfa-2a + Ribavirin</arm_group_label>
    <arm_group_label>100 mg INX-08189 + Pegylated interferon alfa-2a + Ribavirin</arm_group_label>
    <arm_group_label>Placebo + Pegylated interferon alfa-2a + Ribavirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Tablet, Oral, 500 or 600 mg weight dependent, Twice daily (BID), 12 weeks</description>
    <arm_group_label>25 mg INX-08189 + Pegylated interferon alfa-2a + Ribavirin</arm_group_label>
    <arm_group_label>50 mg INX-08189 + Pegylated interferon alfa-2a + Ribavirin</arm_group_label>
    <arm_group_label>100 mg INX-08189 + Pegylated interferon alfa-2a + Ribavirin</arm_group_label>
    <arm_group_label>Placebo + Pegylated interferon alfa-2a + Ribavirin</arm_group_label>
    <arm_group_label>100 mg INX-08189 + Ribavirin</arm_group_label>
    <arm_group_label>200 mg INX-08189 + Ribavirin</arm_group_label>
    <arm_group_label>Daclatasvir + INX-08189 50 mg + Ribavirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INX-08189</intervention_name>
    <description>Tablet, Oral, 200 mg, QD, 12 weeks</description>
    <arm_group_label>200 mg INX-08189 + Ribavirin</arm_group_label>
    <arm_group_label>Daclatasvir + INX-08189 200 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daclatasvir</intervention_name>
    <description>Tablet, Oral, 60 mg, QD, 12 weeks</description>
    <arm_group_label>Daclatasvir + INX-08189 100 mg</arm_group_label>
    <arm_group_label>Daclatasvir + INX-08189 200 mg</arm_group_label>
    <arm_group_label>Daclatasvir + INX-08189 50 mg + Ribavirin</arm_group_label>
    <other_name>BMS-790052</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

        Amendment 4: Genotype 1, 10 subjects at site 401.

          -  Males and females, 18 to 65 years of age inclusive with a body mass index (BMI) of at
             least 18 kg/m2 but not exceeding 36 kg/m2

          -  Diagnosed with chronic HCV at least 6 months prior to Visit 1 with medical
             documentation (e.g., prior PCR result, prior liver biopsy, prior genotyping, etc.),
             with a positive HCV viral load of at least 50,000 IU/mL at Visit 1 (screening) as
             measured by quantitative PCR

          -  Chronic genotype 2 or 3 HCV infection (per polymerase chain reaction [PCR]
             methodology)

          -  HCV treatment-naïve where &quot;treatment-naïve&quot; is defined as no prior treatment with IFN
             alfa 2a or 2b, Pegylated IFN alfa-2a, Ribavirin, or any HCV direct-acting anti-viral
             drugs

          -  Liver biopsy consistent with chronic HCV infection but with a classification of
             non-cirrhotic (and without classification of 'transition to cirrhosis or borderline
             cirrhosis') as judged by a pathologist (defined as Knodell ≤ 3, Metavir ≤ 2, Ishak ≤
             4, or Batts &amp;Ludwig ≤ 2 ) within the last two years and before Visit 2 (biopsy can be
             done after Visit 1 and before Visit 2, within the screening period)

          -  Negative urine drug screen for drugs of abuse and methadone (via central lab-provided
             dipstick at site) at screening (Visit 1) (note: subjects with a valid prescription for
             a drug which can be abused [e.g., benzodiazepine, opiates] can be enrolled on the
             judgment of the investigator)

          -  Females will have a negative serum beta human chorionic gonadotropin (βHCG) pregnancy
             test at screening and a negative urine dipstick pregnancy test on Study Day 0 (visit
             2)

          -  Agreement by both female subjects of childbearing potential and male subjects (who
             have not been surgically sterilized) to practice an acceptable method of birth
             control, which includes at least one barrier during the study and for at least 6
             months after the cessation of treatment. Surgical sterilization of either the female
             or the male partner must have occurred at least 6 months prior to the first dose and
             females must be post-menopausal for 2 years to be considered of non-child-bearing
             potential. Acceptable contraceptive methods include one of the following: Oral and
             implantable hormonal contraceptives by the female partner for at least 3 months prior
             to the first dose of Study Drug with additional use of a barrier method, IUD in place
             for at least 6 months prior to first dose with additional use of barrier method.
             Acceptable barrier methods include either diaphragm with spermicide, and condom with
             spermicide. (Note: Abstinence is not an acceptable method of birth control, subjects
             who indicate sexual inactivity must agree to utilize an acceptable method of birth
             control in the event of sexual activity)

          -  Willing and able to complete all study visits and procedures, and able to effectively
             communicate with the investigator and other testing center personnel

          -  Signed informed consent form (ICF) executed prior to protocol screening assessments

        Exclusion Criteria:

          -  Signs or symptoms of decompensated liver disease such as variceal bleeding, ascites,
             hepatic encephalopathy, active jaundice defined by an indirect bilirubin &gt; 2, Alanine
             transaminase (ALT) or Aspartate aminotransferase (AST) laboratory values ≥ 10 times
             the upper limit of normal, or other evidence of decompensated liver disease, or
             hepatocellular carcinoma

          -  Chronic liver disease other than HCV not limited to Hepatitis B virus (HBV) [positive
             test for hepatitis B surface antigen (HBsAg)], hemochromatosis, auto-immune hepatitis,
             alcoholic liver disease or non-alcoholic fatty liver disease

          -  History of liver transplantation

          -  Co-infection with Human immunodeficiency virus (HIV) [positive test for anti-HIV Ab]
             or use of didanosine

          -  History of a heart attack, cardiac ischemia, heart disease, clinically symptomatic
             cardiac abnormalities, or blood clots, based on medical history or apparent on
             physical exam

          -  QTcF interval at Visit 1 of greater than or equal to 450 ms by Fridericia's
             correction, or a personal or family history of Torsades de Pointe

          -  History or presence of sarcoidosis or pancreatitis

          -  History or presence of severe pulmonary function impairment including severe (&gt; GOLD
             stage III) chronic obstructive pulmonary obstructive disease, and moderate to severe
             asthma

          -  Uncontrolled diabetes mellitus as evidenced by HbA1C ≥ 8.5% at screening (Visit 1)

          -  Use of the following medications concurrently or within the 30 days prior to Screening
             (Visit 1) associated with QT prolongation: macrolides, antiarrhythmic agents, azoles,
             fluoroquinolones, and tricyclic anti-depressants (specifically excluded medication
             will be listed in protocol Section 6.8)

          -  Use of immunosuppressive or immune-modulating agents (including azathioprine,
             corticosteroids and immunosuppressive agents) or presence of an
             immunologically-mediated autoimmune disease (other than asthma) or history of solid
             organ or bone marrow transplantation (note: inhaled steroids for mild/moderate asthma
             and topical steroid for minor skin conditions allowed and washout period for per Oral
             (PO)/Intramuscular (IM)/ Intravenous (IV) corticosteroid use is 8 weeks; washout
             periods for other immunosuppressives determined by Medical Monitor)

          -  Use of strong CYP3A4-inhibiting protease inhibitors (specifically Atazanavir,
             Indinavir, Nelfinavir, Saquinavir, and Ritonavir), strong CYP3A4 inhibitors
             (specifically Clarithromycin, Itraconazole, Ketoconazole, Nefazodone, Telithromycin),
             or strong CYP3A4 inducers (specifically Rifampin, Efavirenz, Etravirine,
             Phenobarbital, Phenytoin, and Carbamazepine)

          -  Absolute neutrophil count of &lt; 1800 cells/mm3, or platelet count &lt; 130,000 cells/mm3,
             or hemoglobin &lt; 12 g/dl for women and &lt; 13 g/dl for men, or a history of anemia,
             sickle cell anemia, or thalassemia; (note: if baseline value within 5% of minimum
             qualifying value, one re-test allowed for the purpose of qualifying for study)

          -  A history or presence of abnormal thyroid function that is not adequately controlled
             [defined as Thyroid-stimulating hormone (TSH) levels less than 0.8 x lower limit of
             normal (LLN) or greater than 1.2 x the upper limit of normal (ULN)]

          -  Creatinine clearance &lt; 50 mL/minute, serum creatinine concentration ≥ 1.5 times the
             ULN, or albumin ≤ 3 g/dl

          -  Presence or history of bipolar disorder, schizophrenia, psychosis, or unstable
             psychiatric condition, or hospitalization for psychiatric condition, or suicide
             attempt. (Note: Subjects with psychiatric conditions need to be adequately treated and
             on stable doses of appropriate medications for at least 3 months prior to Visit 1.
             History of suicidal ideation within prior 3 months is exclusionary)

          -  Any malignancy within the last 5 years other than treated cervical carcinoma in situ
             or treated basal cell carcinoma with no more than 20% risk of recurrence within 2
             years

          -  Alcohol abuse by the assessment of the investigator within the past 2 years or an
             alcohol use pattern that will interfere with the study conduct

          -  Drug abuse by the assessment of the investigator within the last six months

          -  Pregnancy, current lactation in female subjects, or male subjects with partners who
             are pregnant, or females intending to become pregnant

          -  Major surgery within 30 days prior to Visit 1

          -  Participation in another clinical trial of an investigational drug or device within 6
             months prior to Visit 1 unless that prior participation involved exposure only to
             placebo by clear and available documentation

          -  Donation of blood or plasma within 30 days prior to Visit 1 (not including routine
             laboratory assessments)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Acri Phase One</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Health Dba Scripps Clinical Research Services</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quest Clinical Research</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Cancer Centers, Llc.</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Options Health Research, Llc</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alamo Medical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2011</study_first_submitted>
  <study_first_submitted_qc>August 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2011</study_first_posted>
  <disposition_first_submitted>September 23, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>September 23, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 9, 2015</disposition_first_posted>
  <last_update_submitted>October 12, 2015</last_update_submitted>
  <last_update_submitted_qc>October 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Inhibitex</keyword>
  <keyword>Chronic Hepatitis</keyword>
  <keyword>Hepatitis C Virus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

